Novavax could receive UK regulatory authorisation for its vaccine as early as this month after releasing impressive UK trial data.
There, it will be manufactured locally but in Australia it will need to be imported because of a lack of capable vaccine manufacturers.
However, the ABC understands Novavax has been in early-stage talks with Australia's biopharmaceutical sector to explore options to outsource some of its supply locally.
IDT Price at posting:
29.0¢ Sentiment: Buy Disclosure: Held
